Singapore: Australian drug discovery and development company Alchemia has appointed Dr Susan Kelley and Mr Nathan Drona as additional non-executive directors to its board as part of a larger board realignment reflecting the importance of the North American and European markets.

Alchemia chairman, Dr Mel Bridges, said that Dr Kelley and Mr Drona bring substantial drug development, oncology, investment banking and biotechnology experience to the company.

"We are extremely pleased and very fortunate to attract two professionals with this kind of experience. It is testimony to the company's high quality assets and opportunity for future development. These US appointments will substantially assist our endeavour to position Alchemia and Audeo as global biopharma companies, with a solid presence in North America and Europe," Dr Bridges added.